MedTrace Logo

Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma

NCT07518602 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2026-04-08

No results posted yet for this study

Summary

This is a single-arm, multicenter phase Ⅱ study to evaluate the therapeutic efficacy and safety of chidamide + sintilimab + bevacizumab in subjects with advanced extrapulmonary neuroendocrine carcinoma who have failed first-line standard therapy. The primary purpose is to assess the objective response rate (ORR) of chidamide + sintilimab + bevacizumab in the above-mentioned subjects, with a planned enrollment of 34 subjects with advanced extrapulmonary neuroendocrine carcinoma who have failed first-line standard therapy.

Conditions

  • Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)

Interventions

DRUG

Chidamide

20 mg of chidamide administered orally twice a week (BIW) 30 minutes after meals

DRUG

Sintilimab

200 mg of sintilimab administered via intravenous drip once every 3 weeks (Q3W)

DRUG

Bevacizumab

7.5 mg/kg of bevacizumab administered via intravenous drip once every 3 weeks (Q3W)

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Feng Wang, MD, PhD · Sun Yat-sen Univesity Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-27
Primary Completion
2028-03-27
Completion
2028-09-27

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07518602 on ClinicalTrials.gov